Effect of doxorubicin on TRAIL resistance and TRAIL receptor expression in lymphoma cell line SNK-6 cells.
- Author:
Ying-chun ZHANG
1
;
Qun-pei YANG
1
;
Yuan TANG
1
;
Wei-ya WANG
1
;
Jian-bo YU
1
;
Wei-ping LIU
2
Author Information
- Publication Type:Journal Article
- MeSH: Antibiotics, Antineoplastic; pharmacology; Apoptosis; drug effects; Cell Line, Tumor; Cell Survival; drug effects; Dose-Response Relationship, Drug; Doxorubicin; administration & dosage; pharmacology; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lymphoma, Extranodal NK-T-Cell; metabolism; pathology; Receptors, TNF-Related Apoptosis-Inducing Ligand; metabolism; TNF-Related Apoptosis-Inducing Ligand; pharmacology; Tumor Necrosis Factor Decoy Receptors; metabolism
- From: Chinese Journal of Oncology 2013;35(9):651-654
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effect of doxorubicin on TRAIL resistance and TRAIL receptor expression in lymphoma cell line SNK-6 cells.
METHODSSNK-6 cells treated with doxorubicin at different concentrations alone or in combination with tumor necrosis factor related apoptosis inducing ligand (TRAIL). Cell proliferation was evaluated by MTT assay. Apoptosis and the expression of TRAIL receptors were determined by flow cytometry.
RESULTSMTT assay showed that treatment with 100 and 1000 ng/ml doxorubicin for 24 h, the survival rates of SNK-6 cells were (80.9 ± 7.2)% and (53.7 ± 2.8)%, significantly higher than that by treatment combined with 500 ng/ml TRAIL (64.9 ± 1.1)% and (34.0 ± 3.9)%, respectively (P < 0.05). Flow cytometry showed that after treatment with 100 and 1000 ng/ml doxorubicin for 48 h, the survival rates of SNK-6 cells were (69.9 ± 6.1)% and (31.1 ± 1.9)%, while treated in combination with 500 ng/ml TRAIL, the cell survival rates were (37.5 ± 6.4)% and (15.0 ± 1.8)%, respectively. The early apoptosis rate was (14.8 ± 0.6)% and (30.8 ± 1.5)%, significantly lower than that [(28.7 ± 0.6)% and (46.6 ± 2.8)%] after treatment in combination with TRAIL (P < 0.05). The expressions of TRAIL receptors and decoy receptors were increased when SNK-6 cells were treated with 100 ng/ml doxorubicin for 24 hours.
CONCLUSIONSDoxorubicin can overcome to a certain extent the TRAIL resistance of SNK-6 cells and induce upregulation of TRAIL death receptors and decoy receptors on the surface of SNK-6 cells. However, a higher dose is needed.
